Salarius Pharmaceuticals Files 8-K: "Other Events"
Ticker: DCOY · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1615219
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Salarius Pharma filed an 8-K for 'Other Events' on Aug 27, 2025 - details TBD.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. The company, formerly known as Flex Pharma, Inc., is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This 8-K filing indicates that Salarius Pharmaceuticals has reported significant events to the SEC, but the lack of specific details leaves investors and the market uncertain about the company's current developments.
Risk Assessment
Risk Level: medium — The filing is for 'Other Events' without specific details, creating uncertainty and potential risk for investors.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- August 27, 2025 (date) — Date of Report
- Flex Pharma, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Houston, TX (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Salarius Pharmaceuticals, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' beyond the general categorization.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on August 27, 2025.
What was Salarius Pharmaceuticals, Inc. formerly known as?
Salarius Pharmaceuticals, Inc. was formerly known as Flex Pharma, Inc.
In which state is Salarius Pharmaceuticals, Inc. incorporated?
Salarius Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Salarius Pharmaceuticals, Inc.?
The principal executive office address is 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
Filing Stats: 993 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2025-08-27 16:10:04
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
- $1.00 — an the minimum bid price requirement of $1.00 per share. Normally, a company would ha
Filing Documents
- flks-20250827.htm (8-K) — 30KB
- 0001615219-25-000119.txt ( ) — 145KB
- flks-20250827.xsd (EX-101.SCH) — 2KB
- flks-20250827_lab.xml (EX-101.LAB) — 22KB
- flks-20250827_pre.xml (EX-101.PRE) — 13KB
- flks-20250827_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On August 27, 2025, Salarius Pharmaceuticals, Inc. ("Salarius") received notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Hearings Panel") has granted Salarius an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard") by October 20, 2025. With respect to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"), Salarius effected a 1-for-15 reverse stock split on August 15, 2025 and expects to regain compliance with the Minimum Bid Price Requirement by Nasdaq's deadline of August 29, 2025. As previously disclosed, on April 23, 2025, Salarius received written notice (the "Delisting Notice") from Nasdaq notifying Salarius that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius' common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. Normally, a company would have been afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), Salarius was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) because Salarius had effected a reverse stock split during the prior one-year period. In addition, as previously disclosed, on March 26, 2025, Salarius received a letter from Nasdaq notifying Salarius that, based on its Form 10-K for the year ended December 31, 2024, Salarius no longer complied with the Equity Standard. The letter indicated that Salarius had until May 12, 2025, to either regain compliance with the Equity Standard or submit a plan to Nasdaq to regain compliance with the Equity Standard (a "Compliance Plan"). However, pursuant to Nasdaq Listing Rule 5810(d)(2), Salarius' failure to comply with the Minimum Bid Price Requirement served as a separate and additional reason for delisting an
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the reverse split and the timing thereof, Salarius' ability to regain compliance with the Minimum Bid Price Requirement by August 29, 2025 and Salarius' ability to regain compliance with the Equity Standard by October 20, 2025. The risks and uncertainties relating to the Company include general market conditions as well as other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and other filings. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: August 27, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Acting Chief Executive Officer, Executive Vice President & Chief Financial Officer